DAVIS, Calif., May 01, 2018 -- Marrone Bio Innovations, Inc. (NASDAQ:MBII) (MBI), a leading provider of bio-based pest management and plant health products for agriculture, turf and ornamental and water treatment markets, today announced that management will attend the 3rd Annual RHK Capital Disruptive Growth & Healthcare Conference in New York City on May 8, 2018.
On Tuesday, May 8, 2018, Marrone Bio Innovations will co-host a content panel titled “Disrupting Productivity/Sustainability, Farming & Animal Health” scheduled to start at 8:15 a.m. Eastern Daylight time. In addition, management is scheduled to present at 10:20 a.m. Eastern Daylight time, also on Tuesday.
Registration is mandatory. For more information about the conference, please visit www.DisruptNYC.com.
About Marrone Bio Innovations
BIO WITH BITE.
Marrone Bio Innovations, Inc. (NASDAQ:MBII) strives to lead the movement to a more sustainable world through the discovery, development and promotion of biological products for pest management and plant health. MBI’s effective and environmentally responsible pest management solutions help customers operate more sustainably while uniquely improving plant health and increasing crop yields. MBI’s currently available commercial products are Regalia®, Grandevo®, Venerate®, Majestene®, Haven® StargusTM, AmplitudeTM, ZeltoTM and Zequanox®. MBI also distributes Bio-tam 2.0® for Isagro USA and Jet-Ag® for Jet Harvest in most regions of the U.S.
Marrone Bio Innovations is dedicated to pioneering smart biopesticide solutions that support a better tomorrow for both farmers, turf managers and consumers around the globe. For more information, please visit www.marronebio.com.
Marrone Bio Innovations Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the potential benefits of the Company’s products, and MBI’s efforts with respect to expansion of its product labels in international markets. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing MBI’s products n global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, and adverse decisions by regulatory agencies and other relevant third parties. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the SEC. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.
Marrone Bio Innovations Contacts:
Pam Marrone, CEO and Founder
Telephone: +1 (530) 750-2800
Email: [email protected]
Investor Relations:
Greg Falesnik
Managing Director
MZ Group – MZ North America
Main: 949-385-6449
[email protected]
www.mzgroup.us


SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 



